Company Overview - Huangshan Capsule Co., Ltd. is located in Anhui Province and was established on August 12, 1996, with its listing date on October 25, 2016 [2] - The company specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules [2] - The revenue composition includes gelatin hollow capsules (64.54%), enteric-coated gelatin hollow capsules (19.22%), and plant capsules and others (16.24%) [2] Stock Performance - As of September 23, the stock price of Huangshan Capsule decreased by 2.01% to 7.32 CNY per share, with a total market capitalization of 2.189 billion CNY [1] - Year-to-date, the stock price has increased by 18.16%, but it has seen a decline of 5.91% over the last five trading days, 9.85% over the last 20 days, and 1.88% over the last 60 days [2] Financial Performance - For the period from January to June 2025, Huangshan Capsule achieved a revenue of 244 million CNY, representing a year-on-year growth of 3.66% [2] - The net profit attributable to the parent company was 35.55 million CNY, showing a year-on-year increase of 19.78% [2] Shareholder Information - As of June 30, 2025, the number of shareholders was 17,900, a decrease of 2.57% from the previous period [2] - The average circulating shares per person increased by 2.64% to 16,197 shares [2] - The company has distributed a total of 125 million CNY in dividends since its A-share listing, with 62.81 million CNY distributed over the last three years [3] Institutional Holdings - As of June 30, 2025, among the top ten circulating shareholders, Jinyuan Shun'an Yuanqi Flexible Allocation Mixed Fund (004685) held 1.6367 million shares, an increase of 129,400 shares from the previous period [3] - Nu'an Multi-Strategy Mixed A Fund (320016) entered as a new shareholder, holding 1.3943 million shares [3]

了解2025年上海辖区上市公司集体接待日，请点击：https://rs.p5w.net/html/175611728073329.shtml 就新品开发以及推广计划，吴克兢称，公司根据产品储备情况，进行改良性新药的研发；对储备品种开 展二次升级开发；与科研院校开展深度合作，积极开展化学药、中成药、新产品、中药大健康产品的开 发工作，推进研发创新。 谈及海外市场情况，吴克兢介绍，公司的控股孙公司贵州广得利医药用品有限公司，其主要产品为明胶 空心胶囊、植物胶囊（HPMC纤维素空心胶囊、普鲁兰多糖空心胶囊）。2024年起，该公司产品出口到 北美（美国、加拿大）、南美（巴西等）、澳洲、欧洲（西班牙、德国）及东南亚地区。2025年，受关 税因素影响，该公司暂停向美国出口产品。截至2025年半年度实现出口业务收入1,833,947.39元，占公 司营业收入总额的0.19%。除此外，公司暂无海外市场拓展计划。（全景网） 为进一步加强与投资者的互动交流，神奇制药（600613.SH）于9月19日（周五）15:00-17:00参加由上海 上市公司协会与全景网联合举办，主题为"沟通传递价值 信心共筑未来"——2025年上海辖区上 ...

Company Overview - Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, being one of the earliest manufacturers in China with over thirty years of high-quality production history [1][2] - The company has a strong reputation in the pharmaceutical hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] Financial Performance - For Q1 2025, the company reported revenue of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, reflecting a year-on-year growth of 22.90% [2] - The sales gross margin for the same period was 29.26% [2] Market Position - As of August 19, the company's stock closed at 8.06 yuan, with a PE ratio of 45.69, compared to the industry average of 59.49 and the industry median of 40.19 [1][2] - The total market capitalization of Huangshan Capsule is 2.411 billion yuan [1] Shareholder Information - As of March 31, 2025, the number of shareholders is 18,378, a decrease of 26 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

Core Insights - Huangshan Capsule's stock closed at 8.18 yuan, up 1.11%, with a rolling PE ratio of 46.37 times and a total market capitalization of 2.447 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 55.70 times and a median of 39.08 times, placing Huangshan Capsule at the 84th position in the industry ranking [1] - As of the first quarter of 2025, only one institution holds shares in Huangshan Capsule, with a total of 18,000 shares valued at 0.00 billion yuan [1] Company Overview - Anhui Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules [1] - The company is one of the earliest manufacturers of medicinal hollow capsules in China, boasting over 30 years of high-quality production history [1] - Huangshan Capsule has a strong reputation in the medicinal hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] Financial Performance - In the first quarter of 2025, the company reported an operating income of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, reflecting a year-on-year growth of 22.90% [2] - The sales gross margin for the company stands at 29.26% [2] Industry Comparison - Huangshan Capsule's PE (TTM) is 46.37, compared to the industry average of 55.70 and the industry median of 39.08 [2] - The company’s market capitalization is 2.447 billion yuan, while the industry average market capitalization is 11.731 billion yuan [2]

Core Viewpoint - Huangshan Capsule's stock closed at 8.19 yuan on August 4, with a 1.74% increase, and a rolling PE ratio of 46.43, marking a new low in 373 days, with a total market value of 2.45 billion yuan [1] Company Overview - Anhui Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, being one of the earliest manufacturers in China with over 30 years of high-quality production history [1] - The company has a strong reputation in the pharmaceutical hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] Financial Performance - In the latest quarterly report for Q1 2025, the company achieved an operating income of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, reflecting a year-on-year growth of 22.90%, with a gross profit margin of 29.26% [2] Market Position - Huangshan Capsule's PE ratio of 46.43 is below the industry average of 54.31 and the industry median of 38.11, ranking 84th in the medical device sector [1][2] - The company’s market value stands at 2.45 billion yuan, compared to the industry average market value of 11.617 billion yuan [2] Capital Flow - On August 4, the net inflow of main funds into Huangshan Capsule was 764,500 yuan, although the overall trend over the past five days showed a net outflow of 4.3336 million yuan [1]

Company Overview - Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, with over 30 years of high-quality production history [1] - The company is one of the earliest manufacturers of pharmaceutical hollow capsules in China and has a high reputation in the industry [1] Financial Performance - For Q1 2025, the company reported operating revenue of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, up 22.90% year-on-year [2] - The sales gross margin for the same period was 29.26% [2] Market Position - The company's current price-to-earnings (PE) ratio is 44.84, compared to the industry average of 54.89 and the industry median of 37.06 [2] - Huangshan Capsule's total market capitalization is 2.366 billion yuan [1] Industry Context - The medical device industry, where Huangshan Capsule operates, has an average PE ratio of 54.89 and a median of 37.06 [2] - Huangshan Capsule ranks 83rd in terms of PE ratio within its industry [1] Capital Flow - On July 31, the company experienced a net outflow of main funds amounting to 2.725 million yuan, with a total outflow of 3.7357 million yuan over the past five days [1]

Company Overview - Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, being one of the earliest manufacturers in China with over 30 years of high-quality production history [1][2] - The company has a strong reputation in the pharmaceutical hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] Financial Performance - For Q1 2025, the company reported revenue of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, reflecting a year-on-year growth of 22.90% [2] - The sales gross margin for the same period was 29.26% [2] Market Position - As of July 16, the company's stock closed at 7.76 yuan, with a PE ratio of 43.99, marking a new low in 353 days, and a total market capitalization of 2.321 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical device sector is 51.87, with a median of 37.48, placing Huangshan Capsule at the 84th position in the industry ranking [1][2] Shareholder Information - As of March 31, 2025, the number of shareholders for Huangshan Capsule was 18,378, a decrease of 26 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

Core Viewpoint - Huangshan Capsule's stock closed at 7.23 yuan on June 24, with a 2.55% increase, resulting in a rolling PE ratio of 40.98 times and a total market value of 2.162 billion yuan [1] Company Overview - Anhui Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, being one of the earliest manufacturers in China with over 30 years of high-quality production history [1] - The company has a strong reputation in the pharmaceutical hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] Financial Performance - In the first quarter of 2025, the company reported an operating income of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, reflecting a year-on-year growth of 22.90% with a sales gross margin of 29.26% [2] - The company's PE ratio (TTM) stands at 40.98, while the industry average is 49.12, and the industry median is 36.07 [2] Market Position - Huangshan Capsule ranks 84th in the industry based on PE ratio, with the medical device industry average PE at 49.12 and the median at 36.07 [1][2] - The company has received several accolades, including the "Anhui Famous Brand Product" for its "Jingchuan" brand gelatin hollow capsules and recognition as an excellent product brand in the pharmaceutical excipients sector [1]

Core Viewpoint - Huangshan Capsule's stock closed at 7.41 yuan, up 1.51%, with a rolling PE ratio of 42.00, marking a new low in 325 days, and a total market value of 2.216 billion yuan [1][2] Company Overview - Anhui Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, being one of the earliest manufacturers in China with over 30 years of high-quality production history [1] - The company has a strong reputation in the pharmaceutical hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] Financial Performance - In Q1 2025, the company achieved an operating income of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, up 22.90% year-on-year, with a gross profit margin of 29.26% [2] Market Position - Huangshan Capsule ranks 84th in the industry based on PE ratio, with the average PE ratio for the medical device industry at 50.64 and the median at 37.05 [2] - The average market value of the industry is 10.91 billion yuan, while Huangshan Capsule's market value is 2.216 billion yuan [2] Shareholder Information - As of March 31, 2025, Huangshan Capsule had 18,378 shareholders, a decrease of 26 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

6月3日，黄山胶囊今日收盘7.26元，上涨1.40%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到41.15倍，创321天以来新低，总市值21.71亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均50.80倍，行业中值36.71倍，黄山胶囊排 名第84位。 资金流向方面，6月3日，黄山胶囊主力资金净流入441.15万元，近5日总体呈流入状态，5日共流入 282.42万元。 安徽黄山胶囊股份有限公司的主营业务是明胶空心胶囊和肠溶明胶空心胶囊的研发、生产与销售。公司 的主要产品是明胶空心胶囊、肠溶明胶空心胶囊、羟丙甲纤维素空心胶囊、普鲁兰多糖空心胶囊。公司 是中国最早的药用空心胶囊生产企业之一，拥有三十多年高品质药用空心胶囊生产历史。在药用空心胶 囊行业，公司具有较高的知名度，现为中国医药包装协会突出贡献奖成员单位、药用空心胶囊专业委员 会副主任单位之一。公司的商标被评为安徽省著名商标，"旌川"牌药用空心胶囊获"安徽名牌产品"称 号。"旌川"牌明胶空心胶囊和肠溶明胶空心胶囊荣获"中国化学制药行业药用辅料优秀产品品牌"。 最新一期业绩显示，2025年一季报，公司实现营业收入1.19亿元 ...